Stock listing
B3:A1ZN34 AstraZeneca PLC Ações
Brazilian listing (B3) of AstraZeneca PLC · home listing LSE:AZN
Follow AstraZeneca PLC into a list and get an email when it puts out news.
Share price · BMFBOVESPA:A1ZN34
174.09 BRL -1.91 (-1.1%)
Close on Nov 19, 2026
- Day range
- 172.28 – 174.09 BRLNov 19, 2026
- Volume
- 179 sharesNov 19, 2026
- Market cap
- 1.62T BRLAt the close on Nov 19, 2026 · price × 9.31B shares outstanding
- 52-week range
- 129.48 – 190.40 BRLLowest and highest trades, Nov 21, 2025 – Nov 19, 2026
- Traded on an average day
- 125,643 BRLMedian day 194 shares · last 3 months, Aug 19, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:AZN · Home | 13,412p GBX (pence) | -234 (-1.7%) | 2,180,343 | 13,432p | 13,538p | 13,350p | 13,646p | Close on Nov 20, 2026 |
| NYSE:AZN | $174.35 USD | -1.06 (-0.6%) | 2,022,735 | $176.14 | $177.47 | $174.04 | $175.41 | Close on Nov 20, 2026 |
| Stockholm:AZN | 1,796.00 SEK | +18.50 (+1.0%) | 462,554 | 1,790.00 | 1,812.00 | 1,784.50 | 1,777.50 | Close on Nov 20, 2026 |
| Frankfurt:ZEG | €159.55 EUR | -2.15 (-1.3%) | — | €159.60 | €161.50 | €159.20 | €161.70 | Close on Nov 20, 2026 |
| B3:A1ZN34 | 174.09 BRL | -1.91 (-1.1%) | 179 | 173.57 | 174.09 | 172.28 | 176.00 | Close on Nov 19, 2026 |
| Stuttgart:ZEG | €158.95 EUR | -0.75 (-0.5%) | 56 | €158.35 | €161.05 | €158.35 | €159.70 | Close on Nov 20, 2026 |
| Munich:ZEG | €158.35 EUR | -0.95 (-0.6%) | — | €158.90 | €158.90 | €158.35 | €159.30 | Close on Nov 20, 2026 |
| Hamburg:ZEG | €160.10 EUR | +1.60 (+1.0%) | — | €158.45 | €160.10 | €158.40 | €158.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 6, 2026 · BMFBOVESPA:A1ZN34 · BRL, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 170.69 | -1.58 | -0.9% | 166.48 | 171.35 | 165.94 | 144 | |
| 172.27 | +1.00 | +0.6% | 172.27 | 172.27 | 172.27 | 482 | |
| 171.27 | +4.00 | +2.4% | 171.57 | 173.33 | 171.01 | 311 | |
| 167.27 | -3.07 | -1.8% | 170.27 | 171.34 | 167.27 | 543 | |
| 170.34 | +14.13 | +9.0% | 166.50 | 170.34 | 166.50 | 2,867 | |
| 156.21 | +4.47 | +2.9% | 153.00 | 157.01 | 153.00 | 834 | |
| 151.74 | +0.59 | +0.4% | 150.47 | 153.16 | 150.47 | 83 | |
| 151.15 | -2.10 | -1.4% | 151.88 | 152.89 | 150.70 | 3,100 | |
| 153.25 | +20.10 | +15.1% | 152.10 | 158.74 | 152.10 | 3,358 | |
| 133.15 | -11.57 | -8.0% | 146.17 | 146.17 | 133.15 | 3,934 | |
| 144.72 | +2.72 | +1.9% | 142.00 | 145.95 | 142.00 | 2,069 | |
| 142.00 | +1.14 | +0.8% | 141.79 | 142.00 | 141.26 | 114 | |
| 140.86 | +2.47 | +1.8% | 141.00 | 141.00 | 140.86 | 887 | |
| 138.39 | -1.51 | -1.1% | 138.67 | 138.67 | 138.16 | 236 | |
| 139.90 | -1.84 | -1.3% | 143.33 | 143.33 | 138.81 | 1,248 | |
| 141.74 | +5.18 | +3.8% | 137.84 | 142.91 | 137.84 | 547 | |
| 136.56 | +5.12 | +3.9% | 133.39 | 136.56 | 133.13 | 20 | |
| 131.44 | -1.46 | -1.1% | 134.04 | 135.16 | 130.46 | 3,825 | |
| 132.90 | +0.24 | +0.2% | 133.40 | 133.40 | 131.77 | 100 | |
| 132.66 | -1.76 | -1.3% | 134.50 | 134.50 | 131.10 | 611 | |
| 134.42 | +2.61 | +2.0% | 132.16 | 134.42 | 132.16 | 1,323 | |
| 131.81 | +0.81 | +0.6% | 131.44 | 132.06 | 130.00 | 1,797 | |
| 131.00 | -5.35 | -3.9% | 132.00 | 132.00 | 129.48 | 1,765 | |
| 136.35 | -1.52 | -1.1% | 137.43 | 137.84 | 136.00 | 3,674 | |
| 137.87 | -2.22 | -1.6% | 139.10 | 139.10 | 137.00 | 346 | |
| 140.09 | -2.61 | -1.8% | 139.84 | 141.44 | 139.48 | 113 | |
| 142.70 | -1.79 | -1.2% | 145.94 | 145.94 | 142.60 | 111 | |
| 144.49 | +0.35 | +0.2% | 144.23 | 144.49 | 144.14 | 261 | |
| 144.14 | +1.90 | +1.3% | 142.68 | 144.14 | 142.68 | 764 | |
| 142.24 | +1.69 | +1.2% | 142.28 | 142.28 | 142.24 | 66 | |
| 140.55 | -8.38 | -5.6% | 142.21 | 142.96 | 140.55 | 522 | |
| 148.93 | +6.20 | +4.3% | 144.05 | 148.93 | 143.11 | 11 | |
| 142.73 | -0.37 | -0.3% | 142.67 | 143.99 | 142.67 | 114 | |
| 143.10 | +0.41 | +0.3% | 143.84 | 143.84 | 142.56 | 56 | |
| 142.69 | -0.94 | -0.7% | 142.59 | 142.75 | 142.18 | 21 | |
| 143.63 | +3.82 | +2.7% | 139.60 | 143.63 | 139.60 | 18 | |
| 139.81 | -0.39 | -0.3% | 138.70 | 140.21 | 138.70 | 58 | |
| 140.20 | +3.40 | +2.5% | 141.19 | 141.32 | 140.20 | 194 | |
| 136.80 | +0.74 | +0.5% | 136.13 | 136.80 | 135.85 | 76 | |
| 136.06 | +2.36 | +1.8% | 136.55 | 136.55 | 135.60 | 47 | |
| 133.70 | -2.10 | -1.5% | 135.60 | 135.60 | 133.70 | 112 | |
| 135.80 | -3.62 | -2.6% | 139.44 | 139.44 | 135.80 | 226 | |
| 139.42 | -0.34 | -0.2% | 139.72 | 139.90 | 137.62 | 2,553 | |
| 139.76 | +1.82 | +1.3% | 139.43 | 141.39 | 138.78 | 7,311 | |
| 137.94 | -1.86 | -1.3% | 141.20 | 141.20 | 137.21 | 124 | |
| 139.80 | -0.75 | -0.5% | 138.53 | 139.80 | 138.53 | 26 | |
| 140.55 | -0.35 | -0.2% | 142.31 | 142.31 | 140.13 | 120 | |
| 140.90 | -1.19 | -0.8% | 141.25 | 141.25 | 140.90 | 5 | |
| 142.09 | -1.01 | -0.7% | 140.23 | 142.37 | 140.23 | 39 | |
| 143.10 | -1.24 | -0.9% | 144.34 | 144.34 | 142.50 | 121 | |
| 144.34 | +1.53 | +1.1% | 145.40 | 145.60 | 144.34 | 43 | |
| 142.81 | +0.44 | +0.3% | 141.80 | 143.20 | 141.26 | 147 | |
| 142.37 | +0.17 | +0.1% | 142.20 | 142.37 | 141.98 | 31 | |
| 142.20 | -0.87 | -0.6% | 144.94 | 144.94 | 141.00 | 805 | |
| 143.07 | +3.96 | +2.8% | 140.00 | 143.07 | 139.06 | 169 |
Splits
1 split · BMFBOVESPA:A1ZN34 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-2 | Consolidation |
- Ticker
- B3:A1ZN34
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- B3
- Currency
- BRL
What changed lately
Latest news release · Nov 16, 2026
Baxfendy recommended for approval in the EU
Latest earnings call · Jul 27, 2026
AstraZeneca (LSE:AZN) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Oct 30, 2026
Q3 2026 Earnings Presentation
Earnings · 153 slides
Latest news
Admission of Further Securities to Trading
Nov 2, 2026
Closed 167.27 (-1.8%) on Nov 3, 2026
Total Voting Rights
Nov 2, 2026
Closed 167.27 (-1.8%) on Nov 3, 2026
3rd Quarter Results
Oct 30, 2026
Closed 170.34 (+9.0%) on Oct 30, 2026
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Oct 27, 2026
Closed 151.15 (-1.4%) on Oct 27, 2026
Enhertu approved in EU for HER2-positive eBC
Oct 27, 2026
Closed 151.15 (-1.4%) on Oct 27, 2026
AstraZeneca PLC on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 184 in the last 12 months · 871 in all · newest Nov 16, 2026 · oldest 2016
- Calls
- 16 calls with a replay · 16 with a transcript · latest Jul 27, 2026
- Decks
- 333 decks · latest Oct 30, 2026
Where AstraZeneca PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:AZN · Home listing | LSE | United Kingdom | GBX |
| NYSE:AZN | NYSE | United States | USD |
| Stockholm:AZN | Stockholm | Sweden | SEK |
| gettex:ZEG | gettex | Germany | EUR |
| BCBA:AZN | BCBA | Argentina | ARS |
| Tradegate:ZEG | Tradegate | Germany | EUR |
| LS Exchange:886455 | LS Exchange | Germany | EUR |
| Frankfurt:ZEG | Frankfurt | Germany | EUR |
| B3:A1ZN34 · This page | B3 | Brazil | BRL |
| BOATS:AZN | BOATS | United States | USD |
| Lang & Schwarz:886455 | Lang & Schwarz | Germany | EUR |
| Aquis:AZNL | Aquis | United Kingdom | GBX |
| BMV:AZNN | BMV | Mexico | MXN |
| BMV:AZN1N | BMV | Mexico | MXN |
| BCBA:AZND | BCBA | Argentina | USD |
| Turquoise:AZNL | Turquoise | United Kingdom | GBX |
| Stuttgart:ZEG | Stuttgart | Germany | EUR |
| Munich:ZEG | Munich | Germany | EUR |
| Aquis:AZNS | Aquis | United Kingdom | SEK |
| BSESOF:ZEG | BSESOF | Bulgaria | EUR |
| BCBA:AZNC | BCBA | Argentina | USD |
| BIVA:AZN1N | BIVA | Mexico | MXN |
| BX Swiss:ZEG | BX Swiss | Switzerland | CHF |
| Aquis:AZNS | Aquis | United Kingdom | SEK |
| Hamburg:ZEG | Hamburg | Germany | EUR |
| Hanover:ZEG | Hanover | Germany | EUR |
| Lang & Schwarz:886715 | Lang & Schwarz | Germany | EUR |
| Turquoise:AZNS | Turquoise | United Kingdom | SEK |
| Dusseldorf:ZEG | Dusseldorf | Germany | EUR |
| LS Exchange:886715 | LS Exchange | Germany | EUR |
| BCBA:AZN.CI | BCBA | Argentina | ARS |
Valuation
P/E 24.6× against a median of 26.7×: 6th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- £227.8B GBP
- P/E
- 24.6×
- EV/sales
- 4.8×
- EV/EBITDA
- 14.1×
- Price/book
- 5.3×
- Gross margin
- 77.6%
- Operating margin
- 23.6%
- Net margin
- 17.7%
- Debt to equity
- 0.7×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Johnson & Johnson · NYSE:JNJ | US$651.1B | US$678.5B | 40.5× | 6.8× | n/a | 8.0× | 16.2% | 0.6× | -0.02 |
| AbbVie Inc. · NYSE:ABBV | US$505.9B | US$503.8B | 48.9× | 7.6× | n/a | n/a | 15.7% | n/a | 0.00 |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| GSK plc · LSE:GSK | US$96.63B | US$123.8B | 17.0× | 2.8× | 9.3× | 3.9× | 13.0% | 1.3× | n/a |
| Median of the others | US$143.4B | US$179.5B | 26.7× | 3.3× | 9.3× | 5.1× | 15.7% | 0.6× | 0.27 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 16329.66 GBX · Analysts' mean
- EPS, year to Dec 2026
- 10.24 · 25 analysts
- Revenue, year to Dec 2026
- 63.38B · 25 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Dunoyer | Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca |
| Pascal Soriot | Executive Director and CEO |
| Aradhana Sarin | Executive Director and CFO |
| Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel |
| David Fredrickson | Executive Vice-President, Oncology Business Unit |
| Iskra Reic | Executive Vice-President, International |
| Pam Cheng | Executive Vice President, Global Operations, IT & Chief Sustainability Officer |
| Ruud Dobber | Executive Vice-President, BioPharmaceuticals Business Unit |
| Sharon Barr | Executive Vice-President, BioPharmaceuticals R&D |
| Susan Galbraith | Executive Vice-President, Oncology R&D |
Board
| Director | Role |
|---|---|
| Michel Demaré | Non-Executive Chair of the Board |
| Anna Manz | Non-Executive Director |
| Aradhana Sarin | Executive Director and CFO |
| Birgit Conix | Non-Executive Director |
| Diana Layfield | Non-Executive Director |
| Euan Ashley | Non-Executive Director |
| Karen Knudsen | Non-Executive Director |
| Marcus Wallenberg | Non-Executive Director |
| Pascal Soriot | Executive Director and CEO |
| Sheri McCoy | Non-Executive Director |
| Tony Mok | Non-Executive Director |
| Wan Ling Martello | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| AstraZeneca (LSE:AZN) Q2 2026 Earnings Call | Mon, Jul 27, 2026 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2026 Earnings Call | Wed, Apr 29, 2026 · 9:30 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2025 Earnings Call | Tue, Feb 10, 2026 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2025 Earnings Call | Tue, Nov 11, 2025 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2025 Earnings Call | Tue, Jul 29, 2025 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2025 Earnings Call | Tue, Apr 29, 2025 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2024 Earnings Call | Thu, Feb 06, 2025 · 6:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2024 Earnings Call | Thu, Jul 25, 2024 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2024 Earnings Call | Thu, Apr 25, 2024 · 6:45 PM ET | Replay |
All 16 calls
| Call | When | Status |
|---|---|---|
| AstraZeneca (LSE:AZN) Q4 2023 Earnings Call | Thu, Feb 08, 2024 · 7:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q3 2023 Earnings Call | Wed, Nov 15, 2023 · 9:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2023 Earnings Call | Fri, Jul 28, 2023 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 6:45 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q4 2022 Earnings Call | Thu, Feb 09, 2023 · 11:00 AM ET | Replay |
| AstraZeneca (LSE:AZN) Q2 2022 Earnings Call | Fri, Jul 29, 2022 · 6:45 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 · After close | −0.7% |
| Q2 2026 | Jul 27, 2026 · Before open | +1.7% |
| Q1 2026 | Apr 29, 2026 · Before open | −1.5% |
| Q4 2025 | Feb 10, 2026 · Before open | +2.0% |
| Q3 2025 | Nov 6, 2025 · Before open | +3.1% |
| Q2 2025 | Jul 29, 2025 · Before open | +3.4% |
| Q1 2025 | Apr 29, 2025 · Before open | +0.9% |
| Q4 2024 | Feb 6, 2025 · Before open | +5.9% |
| Q3 2024 | Nov 12, 2024 · Before open | +0.1% |
| Q2 2024 | Jul 25, 2024 · Before open | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · Before open | +5.9% |
| Q4 2023 | Feb 8, 2024 · Before open | −6.4% |
| Q3 2023 | Nov 9, 2023 · Before open | +2.6% |
| Q2 2023 | Jul 28, 2023 · Before open | +3.4% |
| Q1 2023 | Apr 27, 2023 · Before open | −0.4% |
| Q4 2022 | Feb 9, 2023 · Before open | +4.1% |
| Q3 2022 | Nov 10, 2022 · Before open | +2.9% |
| Q2 2022 | Jul 29, 2022 · Before open | −0.2% |
| Q1 2022 | Apr 29, 2022 · Before open | +1.2% |
| Quarter to Dec 31, 2021 | Feb 10, 2022 · Before open | +3.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 153 slides | Oct 30, 2026 |
| 9M and Q3 2026 Earnings Presentation | Earnings | 46 slides | Oct 30, 2026 |
| ESMO 2026 Investor Event | Conference | 59 slides | Oct 26, 2026 |
| ASBMR 2026 | Conference | 33 slides | Oct 12, 2026 |
| Meet AZN Management @ ERS 2026 | Conference | 35 slides | Sep 8, 2026 |
| H1 2026 Earnings Presentation | Earnings | 154 slides | Jul 27, 2026 |
| H1 2026 Earnings Presentation | Earnings | 43 slides | Jul 27, 2026 |
| ESG Presentation (July 2026) | Sustainability | 16 slides | Jul 6, 2026 |
| Investor Day (June 2026) | Investor day | 55 slides | Jun 8, 2026 |
| ADA 2026 | Conference | 41 slides | Jun 8, 2026 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| ASCO 2026 Investor Event | Conference | 41 slides | Jun 1, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 148 slides | Apr 29, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 40 slides | Apr 29, 2026 |
| Debt Investor Presentation (February 2026) | Debt investors | 40 slides | Feb 10, 2026 |
| FY 2025 Earnings Presentation | Earnings | 163 slides | Feb 10, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 45 slides | Feb 10, 2026 |
| JP Morgan Healthcare Conference 2026 | Conference | 25 slides | Jan 13, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 39 slides | Nov 11, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 156 slides | Nov 6, 2025 |
| ESMO Investor Event 2025 | Conference | 53 slides | Oct 20, 2025 |
| ESC 2025 | Conference | 33 slides | Aug 31, 2025 |
| Debt Investor Presentation (July 2025) | Debt investors | 36 slides | Jul 29, 2025 |
| H1 2025 Earnings Presentation | Earnings | 149 slides | Jul 29, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 41 slides | Jul 29, 2025 |
| ASCO Investor Event 2025 | Conference | 49 slides | Jun 2, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 143 slides | Apr 29, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 40 slides | Apr 29, 2025 |
| Debt Investor Presentation (February 2025) | Debt investors | 34 slides | Feb 6, 2025 |
| FY2024 Earnings Presentation | Earnings | 151 slides | Feb 6, 2025 |
| FY2024 Earnings Presentation | Earnings | 42 slides | Feb 6, 2025 |
| JP Morgan Healthcare Conference 2025 | Conference | 26 slides | Jan 14, 2025 |
| Investor Day (November 2024) | Investor day | 44 slides | Nov 15, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 159 slides | Nov 12, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 38 slides | Nov 12, 2024 |
| Investor Day (November 2024) | Investor day | 40 slides | Nov 4, 2024 |
| Investor Day (September 2024) | Investor day | 55 slides | Sep 16, 2024 |
| Investor Day (September 2024) | Investor day | 40 slides | Sep 9, 2024 |
| Debt Investor Presentation (July 2024) | Debt investors | 33 slides | Jul 25, 2024 |
| H1 2024 Earnings Presentation | Earnings | 151 slides | Jul 25, 2024 |
| H1 and Q2 2024 Earnings Presentation | Earnings | 38 slides | Jul 25, 2024 |
| Investor Day (June 2024) | Investor day | 59 slides | Jun 3, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 147 slides | Apr 25, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 36 slides | Apr 25, 2024 |
| ESG Presentation (March 2024) | Sustainability | 15 slides | March 2024 |
| Debt Investor Presentation (February 2024) | Debt investors | 39 slides | Feb 8, 2024 |
| FY2023 Earnings Presentation | Earnings | 144 slides | Feb 8, 2024 |
| FY2023 Earnings Presentation | Earnings | 45 slides | Feb 8, 2024 |
| JP Morgan Healthcare Conference 2024 | Conference | 26 slides | Jan 9, 2024 |
| Investor Day (2024) | Investor day | 32 slides | 2024 |
| Investor Day (2024) | Investor day | 56 slides | 2024 |
This page holds 50 of 333 decks. Open Decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Notes (four series) Update: €2.55B · Barclays Bank PLC +2 Dealers: Barclays Bank PLC (co-lead), Goldman Sachs International (co-lead), Morgan Stanley (co-lead) Use of proceeds: General corporate purposes | Sep 1, 2026 | US$2.98B |
| Fixed rate notes Announced: US$2B · BofA Securities, Inc. +3 Dealers: BofA Securities, Inc. (co-lead), Deutsche Bank Securities Inc. (co-lead), HSBC Securities (USA) Inc. (co-lead), Mizuho Securities USA LLC (co-lead) Use of proceeds: General corporate purposes, which may include refinancing existing indebtedness | Feb 26, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.7B | 54.1B | 45.8B | 44.4B | 37.4B | 26.6B | 24.4B | 22.1B | 22.5B | 23.0B |
| Cost of revenue | 10.6B | 10.2B | 8.27B | 12.4B | 12.4B | 5.30B | 4.92B | 4.94B | 4.32B | 4.13B |
| Gross profit | 48.1B | 43.9B | 37.5B | 32.0B | 25.0B | 21.3B | 19.5B | 17.2B | 18.1B | 18.9B |
| Research and development | 14.2B | 13.6B | 10.9B | 9.76B | 9.74B | 5.99B | 6.06B | 5.93B | 5.76B | 5.89B |
| Selling, general and administrative | 19.9B | 20.0B | 19.2B | 18.4B | 15.2B | 11.3B | 11.7B | 10.0B | 10.2B | 9.41B |
| Operating income | 13.7B | 10.0B | 8.19B | 3.76B | 1.06B | 5.16B | 2.92B | 3.39B | 3.68B | 4.90B |
| Depreciation and amortization | 5.73B | 5.07B | 5.39B | 5.48B | 6.53B | 3.15B | 3.76B | 2.74B | 2.47B | 2.36B |
| EBITDA | 19.5B | 15.1B | 13.6B | 9.24B | 7.59B | 8.31B | 6.69B | 6.13B | 6.14B | 7.26B |
| Interest expense | 1.69B | 1.74B | 1.63B | 1.35B | 1.30B | 1.31B | 1.43B | 1.42B | 1.51B | 1.38B |
| Income before tax | 12.4B | 8.69B | 6.90B | 2.50B | -265.0M | 3.92B | 1.55B | 1.99B | 2.23B | 3.55B |
| Income tax | 2.17B | 1.65B | 938.0M | -792.0M | -380.0M | 772.0M | 321.0M | -57.0M | -641.0M | 146.0M |
| Net income | 10.2B | 7.04B | 5.96B | 3.29B | 112.0M | 3.20B | 1.33B | 2.15B | 3.00B | 3.50B |
| Earnings per share, basic | 6.60 | 4.54 | 3.84 | 2.12 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.77 |
| Earnings per share, diluted | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 | 2.44 | 1.03 | 1.70 | 2.37 | 2.76 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.71B | 5.49B | 5.84B | 6.17B | 6.33B | 7.83B | 5.37B | 4.83B | 3.32B | 5.02B |
| Short-term investments | 30.0M | 166.0M | 122.0M | 239.0M | 69.0M | 160.0M | 849.0M | 849.0M | 1.23B | 884.0M |
| Receivables | 15.2B | 13.0B | 12.1B | 10.5B | 9.64B | 7.02B | 5.76B | 5.57B | 5.01B | 4.57B |
| Inventory | 6.56B | 5.29B | 5.42B | 4.70B | 8.98B | 4.02B | 3.19B | 2.89B | 3.04B | 2.33B |
| Current assets | 28.7B | 25.8B | 25.1B | 22.6B | 26.2B | 19.5B | 15.6B | 15.6B | 13.2B | 13.3B |
| Property, plant and equipment | 13.0B | 10.3B | 9.40B | 8.51B | 9.18B | 8.25B | 7.69B | 7.42B | 7.62B | 6.85B |
| Goodwill | 21.2B | 21.0B | 20.0B | 19.8B | 20.0B | 11.8B | 11.7B | 11.7B | 11.8B | 11.7B |
| Total assets | 114.1B | 104.0B | 101.1B | 96.5B | 105.4B | 66.7B | 61.4B | 60.7B | 63.4B | 62.5B |
| Accounts payable | 25.3B | 22.5B | 22.4B | 19.0B | 18.9B | 15.8B | 14.0B | 12.8B | 11.6B | 10.5B |
| Current liabilities | 30.6B | 27.9B | 30.5B | 26.3B | 22.6B | 20.3B | 18.1B | 16.3B | 16.4B | 15.3B |
| Long-term debt | 24.7B | 26.5B | 22.4B | 23.0B | 28.1B | 17.5B | 15.7B | 17.4B | 15.6B | 14.5B |
| Total debt | 29.6B | 30.3B | 28.6B | 29.2B | 30.8B | 20.4B | 18.2B | 19.1B | 17.8B | 16.8B |
| Total liabilities | 65.4B | 63.2B | 62.0B | 59.4B | 66.1B | 51.1B | 46.8B | 46.6B | 46.7B | 45.9B |
| Shareholders' equity | 48.7B | 40.8B | 39.1B | 37.0B | 39.3B | 15.6B | 13.1B | 12.5B | 15.0B | 14.9B |
| Shares outstanding | 1.56B | 1.56B | 1.56B | 1.56B | 1.43B | 1.31B | 1.30B | 1.27B | 1.27B | 1.27B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 14.6B | 11.9B | 10.3B | 9.81B | 5.96B | 4.80B | 2.97B | 2.62B | 3.58B | 4.14B |
| Capital spending | -2.81B | -1.92B | -1.36B | -1.09B | -1.09B | -961.0M | -979.0M | -1.04B | -1.33B | -1.45B |
| Free cash flow | 11.8B | 9.94B | 8.98B | 8.72B | 4.87B | 3.84B | 1.99B | 1.57B | 2.25B | 2.70B |
| Cash from investing | -6.81B | -7.98B | -4.06B | -2.96B | -11.1B | -285.0M | -657.0M | 963.0M | -2.33B | -3.97B |
| Cash from financing | -7.54B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B | -1.76B | -2.04B | -2.94B | -1.32B |
| Dividends paid | -4.97B | -4.63B | -4.48B | -4.36B | -3.86B | -3.57B | -3.59B | -3.48B | -3.52B | -3.56B |
| Share buybacks | -521.0M | -81.0M | 3.71B | -920.0M | -149.0M | 3.05B | 314.0M | 2.97B | 2.31B | 2.78B |
| Change in cash | 223.0M | -115.0M | -286.0M | 25.0M | -1.45B | 2.31B | 547.0M | 1.54B | -1.69B | -1.15B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
| 3rd Quarter Results | Oct 30, 2026 | Other filings | London Stock Exchange |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 1,003 filings. Open Filings
Cap table
Built by 6ix from AstraZeneca PLC’s releases · as of Feb 26, 2026
- Common shares
- 1,550,917,690
- Fully diluted
- 1,550,917,690
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,550,917,690 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,550,917,690 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Euan Ashley Other companies: DexCom, Inc. (Director · Since at least Oct 24, 2025) | Non-Executive Director · Since at least Nov 5, 2026 |
| Anna Manz | Non-Executive Director · Since at least Nov 5, 2026 |
| Aradhana Sarin | Executive Director and CFO · Since at least Nov 5, 2026 |
| Birgit Conix | Non-Executive Director · Since at least Nov 5, 2026 |
| David Fredrickson | Executive Vice-President, Oncology Business Unit · Since at least Nov 4, 2026 |
| Diana Layfield | Non-Executive Director · Since at least Nov 5, 2026 |
| Iskra Reic | Executive Vice-President, International · Since at least Jul 27, 2026 |
| Jeff Pott | Chief Human Resources Officer, Chief Compliance Officer and General Counsel · Since at least Nov 4, 2026 |
| Karen Knudsen | Non-Executive Director · Since at least Nov 5, 2026 |
| Mani Sharma | See remarks · Since at least Mar 18, 2026 |
All 22 people
| Person | Seat |
|---|---|
| Marc Dunoyer | Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca · Since at least Oct 22, 2026 |
| Marcus Wallenberg | Non-Executive Director · Since at least Nov 5, 2026 |
| Maria Belvisi | Chief Scientific Officer · Apr 10, 2026 – Nov 5, 2026 · Past |
| Michel Demaré | Non-Executive Chair of the Board · Since at least Jul 27, 2026 |
| Pam Cheng | Executive Vice President, Global Operations, IT & Chief Sustainability Officer · Since at least Oct 30, 2026 |
| Pascal Soriot | Executive Director and CEO · Since at least Oct 30, 2026 |
| Ruud Dobber | Executive Vice-President, BioPharmaceuticals Business Unit · Since at least Sep 23, 2026 |
| Sharon Barr | Executive Vice-President, BioPharmaceuticals R&D · Since at least Sep 8, 2026 |
| Sheri McCoy | Non-Executive Director · Since at least Nov 5, 2026 |
| Susan Galbraith | Executive Vice-President, Oncology R&D · Since at least Oct 25, 2026 |
| Tony Mok | Non-Executive Director · Since at least Nov 4, 2026 |
| Wan Ling Martello | Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about AstraZeneca PLC.